表紙
市場調查報告書
商品編碼
1029392

神經內分泌腫瘤:到 2030 年的全球藥物預測和市場分析

Neuroendocrine Tumors - Global Drug Forecast and Market Analysis to 2030

出版日期: | 出版商: GlobalData | 英文 126 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

神經內分泌腫瘤是一組罕見的異質性腫瘤,可在身體的各個器官中散發。大多數 NEN 是分化良好的神經內分泌腫瘤 (NET),而低分化神經內分泌癌 (NEC) 僅佔所有 NEN 的 10-20%。 62-67%的NETs發生在胃腸道,尤其是小腸、闌尾和大腸。 22-27%的NETs發生在肺中,是NETs含量第二多的部分,而肺中約30%的NETs發生在支氣管系統,即所謂的支氣管肺。大約 7% 的 NET 可以影響胰腺,大約 3% 可以影響胸腺。

自 2021 年以來,神經內分泌癌症市場面臨著一些獨特的趨勢。生長抑素類似物在治療 NET 中非常重要,佔全球市場份額的 55% 左右。此外,該市場約 80% 的價值都受到仿製藥的威脅。這個市場要實現真正的增長,目前市場上的大部分產品都需要被新的管道產品取代。僅有5款產品處於後期開發階段,預計市場規模將從2020年的31億美元增長到2030年的34億美元,8大市場的CAGR為0.9%。

本報告調查了神經內分泌腫瘤市場,概述了疾病和治療方法,以及藥物開發管道的現狀、未滿足的需求和未來的市場競爭趨勢。

目錄

目錄

第 1 章神經內分泌腫瘤:執行摘要

  • 神經內分泌腫瘤市場在 2020 年至 2030 年間以 0.9% 的複合年增長率增長
  • 對影響神經內分泌腫瘤關鍵企業和研發戰略的現有作用機制進行重大改進 為患者匹配最合適的治療仍然是神經內分泌腫瘤中最重要的未滿足需求
  • 後期管線低水平創新擾亂處理局面
  • 醫生的觀點

第 2 章介紹

  • 催化劑
  • 相關報導
  • 未來報告

第 3 章疾病概述

  • 發病機制和病理生理學
    • 發病機制
    • 病理生理學
  • 分類或分期系統

第 4 章流行病學

  • 疾病背景
  • 風險因素和併發症
  • 全球和歷史趨勢
  • 8大市場預測研究方法
    • 來源
    • 預測先決條件和方法:Population-8 大市場
    • 預測的先決條件和方法:NET 診斷髮病率-8 大市場
    • 預測的先決條件和方法:NET 診斷的病例數,按類型
    • 預測的先決條件和方法:NET 診斷的病例數,按階段和類型
    • 預測的先決條件和方法:NET 診斷的病例數、等級和分類
    • 預測的先決條件和方法:NET 診斷的受影響病例數 5 年
  • NET 流行病學預測,2020-2030
    • NET 確診病例數
    • NET 診斷的病例數,按年齡
    • NET 確診病例數、性別
    • NET 診斷的病例數,按類型
    • NET 診斷病例數,按診斷時的類型和階段
    • NET 確診病例數、等級和分類
    • 5 年內 NET 診斷的受影響病例數
  • 討論
    • 流行病學預測見解
    • COVID-19 的影響
    • 分析的局限性
    • 分析的優勢

第 5 章疾病管理

  • 診療概述
  • KOL 對疾病管理的見解
    • 診斷
    • 手術管理
    • 全身治療

第 6 章當前的治療方案

  • 概述

第 7 章未滿足需求和機會的評估

  • 概述
  • 預測性生物標誌物,為患者提供最合適的治療
  • 更安全的低級別腫瘤靶向治療和更有效的高級別腫瘤治療
  • 更明智地使用現有藥物
  • 適合 SSTR 陰性腫瘤的藥物

第 8 章研發戰略

  • 概述
    • 加強 PRRT 經驗證的戰略
    • 一種針對 SSTR 的新方法
    • 用下一代激□抑製劑和免疫檢查點抑製劑替代舊的靶向治療
  • 臨床試驗設計
    • NET 更好的端點
    • 學術贊助的聯合臨床試驗
    • 臨床試驗挑戰

第 9 章管道評估

  • 概述
  • 臨床開發中的有前途的藥物

第 10 章管道評估分析

  • 概述
  • 競爭力評估

第 11 章當前和未來的玩家

  • 概述
  • 交易趨勢

第 12 章市場展望

第 13 章附錄

目錄
Product Code: GDHC230PIDR

Neuroendocrine neoplasms are a group of rare, heterogeneous tumors that can develop sporadically in many different organs of the body. Well-differentiated neuroendocrine tumors (NETs), represent the majority of NENs, and poorly differentiated neuroendocrine carcinomas (NECs), representing only 10-20% of all NENs. 62-67% of NETs occur in the gastrointestinal (GI) tract, specifically in the small intestine, appendix, and large intestine. 22-27% of NETs occur in the lungs, the second most common location of NETs, with about 30% of lung NETs occurring in the bronchial system, so-called bronchopulmonary. Approximately 7% of NETs can develop in the pancreas and 3% in the thymus.

The market of neuroendocrine cancers is facing some unique dynamics beginning in 2021. The class of somatostatin analogs is so important in the treatment of NETs that it represents approximately 55% of the global market share. In total, ~80% of this market's value is under threat of generic competition. For this market to see true growth, the currently marketed products would need to be almost entirely replaced by new pipeline products. With only five products in late-stage development, this is not the case and thus the market value is forecast to increase from $3.1B in 2020 to $3.4B in 2030, at a CAGR of 0.9% in the 8MM.

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of five pipeline therapies, in addition to expansions of currently marketed therapies in new markets during the forecast period.
  • The main barriers to growth in the 8MM are patent expiries and subsequent genericization of the most lucrative agents that are part of the standard of care.
  • Among the late-stage pipeline products and marketed agents, there is tempered key opinion leader (KOL) excitement as a fundamental change in the field is not expected until the end of the forecast period.
  • The most important unmet needs in the ALL market include: Predictive biomarkers to guide personalized therapy, safer targeted therapies for patients with low-grade tumors, and more efficacious therapies for high-grade tumors.

KEY QUESTIONS ANSWERED

  • Five late-stage pipeline agents are expected to enter the Neuroendocrine Tumor market from 2021 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in Neuroendocrine Tumors, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • How has the introduction of Lutathera shaped the 2nd and 3rd lines of therapy? How will the competition fare?
  • What is the expected future uptake of immune checkpoint inhibitors across the 8MM?

Scope

  • Overview of Neuroendocrine Tumors including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline Neuroendocrine Tumors market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Neuroendocrine Tumor therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II - III).
  • Analysis of the current and future market competition in the global Neuroendocrine Tumor therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Neuroendocrine Tumor therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Neuroendocrine Tumor market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global Neuroendocrine Tumor therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Neuroendocrine Tumors: Executive Summary

  • 1.1 The Neuroendocrine Tumor Market Will Grow at a 0.9% CAGR During 2020-2030
  • 1.2 Key Improvements in Existing Mechanisms of Action Form the Dominant Corporate and R&D Strategy in Neuroendocrine Tumors
  • 1.3 Matching a Patient with the Most Appropriate Therapy Remains the Most Important Unmet Need in Neuroendocrine Tumors
  • 1.4 Low Level of Innovation Across the Late-Stage Pipeline to Introduce Minimal Disruption in the Treatment Landscape
  • 1.5 What Do Physicians Think?

2 Introduction

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Disease Overview

  • 3.1 Etiology and Pathophysiology
    • 3.1.1 Etiology
    • 3.1.2 Pathophysiology
  • 3.2 Classification or Staging Systems

4 Epidemiology

  • 4.1 Disease Background
  • 4.2 Risk Factors and Comorbidities
  • 4.3 Global and Historical Trends
  • 4.4 8MM Forecast Methodology
    • 4.4.1 Sources
    • 4.4.2 Forecast Assumptions and Methods: Population - 8MM
    • 4.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs - 8MM
    • 4.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Type
    • 4.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Stage and Type
    • 4.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of NETs by Grade and Differentiation
    • 4.4.7 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of NETs
  • 4.5 Epidemiological Forecast for NETs, 2020-2030
    • 4.5.1 Diagnosed Incident Cases of NETs
    • 4.5.2 Age-Specific Diagnosed Incident Cases of NETs
    • 4.5.3 Sex-Specific Diagnosed Incident Cases of NETs
    • 4.5.4 Diagnosed Incident Cases of NETs by Type
    • 4.5.5 Diagnosed Incident Cases of NETs by Type and Stage at Diagnosis
    • 4.5.6 Diagnosed Incident Cases of NETs by Grade and Differentiation
    • 4.5.7 Five-Year Diagnosed Prevalent Cases of NETs
  • 4.6 Discussion
    • 4.6.1 Epidemiological Forecast Insight
    • 4.6.2 COVID-19 Impact
    • 4.6.3 Limitations of the Analysis
    • 4.6.4 Strengths of the Analysis

5 Disease Management

  • 5.1 Diagnosis and Treatment Overview
  • 5.2 KOL Insights on Disease Management
    • 5.2.1 Diagnosis
    • 5.2.2 Surgical management
    • 5.2.3 Systemic therapy

6 Current Treatment Options

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Predictive Biomarkers to Match a Patient with the Most Appropriate Therapy
  • 7.3 Safer Targeted Therapies for Low-Grade Tumors and More Efficacious Therapies for High-Grade Tumors
  • 7.4 More Informed Use of Currently Available Drugs
  • 7.5 Well-Tolerated Agents for SSTR Negative Tumors

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Enhancing the Validated Strategy of PRRT
    • 8.1.2 Novel Ways to Target SSTRs
    • 8.1.3 Replacing Older Targeted Therapies with Next Generation Kinase Inhibitors and Immune Checkpoint Inhibitors
  • 8.2 Clinical Trials Design
    • 8.2.1 Endpoints More Suitable to NETs
    • 8.2.2 Academically Sponsored and Collaborative Trials
    • 8.2.3 Clinical Trial Challenges

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

  • 10.1 Overview
  • 10.2 Competitive Assessment

11 Current and Future Players

  • 11.1 Overview
  • 11.2 Deal-Making Trends

12 Market Outlook

13 Appendix

List of Tables

List of Tables

  • Table 1: Neuroendocrine tumors: Key Metrics in the 8MM
  • Table 2: Grade and Proliferation Segmentation in Neuroendocrine Tumors
  • Table 3: Risk Factors and Comorbidities for NETs
  • Table 4: Treatment Guidelines for NETs
  • Table 5: Top 10 Deals by Value, 2011-2020
  • Table 6: NET Market - Global Drivers and Barriers, 2020-2030
  • Table 7: Key Events Impacting Sales for NETs in the US, 2020-2030
  • Table 8: NET Market - Drivers and Barriers in the US, 2020-2030
  • Table 9: Key Events Impacting Sales for NETs in the 5EU, 2020-2030
  • Table 10: NET Market - Drivers and Barriers in the 5EU, 2020-2030
  • Table 11: Key Events Impacting Sales for NETs in Japan, 2020-2030
  • Table 12: NET Market - Drivers and Barriers in Japan, 2020-2030
  • Table 13: Key Events Impacting Sales for NETs in China, 2020-2030
  • Table 14: NET Market - Drivers and Barriers in China, 2020-2030
  • Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for NETs in 2020 and 2030
  • Figure 2: Analysis of the Company Portfolio Gap in NETs During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of NETs During the Forecast Period
  • Figure 4: Key Therapeutic Targets in Neuroendocrine Tumors
  • Figure 5: 8MM, Diagnosed Incidence of NETs, Men, Cases per 100,000 Population, All Ages, 2010 and 2020
  • Figure 6: 8MM, Diagnosed Incidence of NETs, Women, Cases per 100,000 Population, All Ages, 2010 and 2020
  • Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of NETs
  • Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Type
  • Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Stage at Diagnosis, by Type
  • Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of NETs by Grade and Differentiation, by Type
  • Figure 11: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of NETs
  • Figure 12: 8MM, Diagnosed Incident Cases of NETs, N, Both Sexes, All Ages, 2020
  • Figure 13: 8MM, Diagnosed Incident Cases of NETs by Age, N, Both Sexes, 2020
  • Figure 14: 8MM, Diagnosed Incident Cases of NETs by Sex, N, All Ages, 2020
  • Figure 15: 8MM, Diagnosed Incident Cases of NETs by Type, N, Both Sexes, 2020
  • Figure 16: 8MM, Diagnosed Incident Cases of NETs by Type and Stage at Diagnosis, N, Both Sexes, All Ages, 2020
  • Figure 17: 8MM, Diagnosed Incident Cases of NETs by Grade and Differentiation, N, Both Sexes, All Ages, 2020
  • Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of NETs, N, Both Sexes, All Ages, 2020
  • Figure 19: Treatment Algorithm for NETs
  • Figure 20: Unmet Needs and Opportunities in Neuroendocrine Tumors
  • Figure 21: Overview of the Development Pipeline in NETs
  • Figure 22: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for NETs in the 8MM During the Forecast Period
  • Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against Afinitor and Lutathera
  • Figure 24: Analysis of the Company Portfolio Gap in NETs During the Forecast Period
  • Figure 25: Global (8MM) Sales Forecast by Country for NETs in 2020 and 2030
  • Figure 26: Sales Forecast by Class for NETs in the US in 2020 and 2030
  • Figure 27: Sales Forecast by Class for NETs in the 5EU in 2020 and 2030
  • Figure 28: Sales Forecast by Class for NETs in Japan in 2020 and 2030
  • Figure 29: Sales Forecast by Class for Neuroendocrine tumors in China in 2020 and 2030